Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 8/20 | 1.00 |
| ▸ | HTR2A | P28223 | 7/20 | 1.00 |
| ▸ | DRD2 | P14416 | 7/20 | 1.00 |
| ▸ | HTR1A | P08908 | 6/20 | 1.00 |
| ▸ | HTR2C | P28335 | 5/20 | 1.00 |
| ▸ | HTR2B | P41595 | 5/20 | 1.00 |
| ▸ | DRD4 | P21917 | 4/20 | 1.00 |
| ▸ | HTR1D | P28221 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | DRD1 | P21728 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mianserin SCHEMBL9122085 | 1.00 | DRD3 (1.00) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL29356897 | 1.00 | DRD3 (1.00) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL23326358 | 1.00 | DRD3 (1.00) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL18020 | 1.00 | DRD3 (1.00) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL9752060 | 0.98 | DRD3 (0.97) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL8344416 | 0.98 | DRD3 (0.97) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL11336834 | 0.98 | HTR2A (0.97) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL340474 | 0.98 | MEN1 (1.00) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL29366576 | 0.98 | MEN1 (1.00) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL2571368 | 0.97 | DRD3 (0.94) | DRD3HTR2ADRD2HTR1AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1323 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| US-11771657-B2 | Methods of delivering a neuroprotective polypeptide to the central nervous system | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-03 | — | — | US | claimed |
| WO-2022182658-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. (US) | 2022-09-01 | — | — | WO | claimed |
| US-20220265563-A1 | METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM | PEPTRON, INC. (KR) | 2022-08-25 | — | — | US | claimed |
| US-20220050117-A1 | GLX-DERIVED MOLECULE DETECTION | GLX ANALYTIX APS (DK) | 2022-02-17 | — | — | US | claimed |
| US-20200046645-A1 | METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM | PEPTRON, INC. (KR) | 2020-02-13 | — | — | US | claimed |
| US-20200038420-A1 | AMINOSTEROL COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING DEPRESSION | ENTERIN, INC. (US) | 2020-02-06 | — | — | US | claimed |
| CN-110191717-A | Methods of delivering neuroprotective polypeptides to the central nervous system | 佩特通公司 | 2019-08-30 | — | — | CN | claimed |
| EP-3528836-A1 | METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM | Peptron, Inc. (KR) | 2019-08-28 | — | — | EP | claimed |
| US-6420401-B1 | SERINE PROTEASE INHIBITOR | WICHITA STATE UNIVERSITY | 2002-07-16 | — | — | US | claimed |
| EP-1032587-A4 | NOVEL EXENDIN AGONIST COMPOUNDS | AMYLIN PHARMACEUTICALS INC (US) | 2002-04-10 | — | — | EP | claimed |
| EP-1011668-A4 | 1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE DERIVATIVES | UNIV WICHITA STATE (US) | 2001-08-16 | — | — | EP | claimed |
| EP-1032587-A1 | NOVEL EXENDIN AGONIST COMPOUNDS | AMYLIN PHARMACEUTICALS, INC. (US) | 2000-09-06 | — | — | EP | claimed |
| EP-1011668-A1 | 1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE DERIVATIVES | THE WICHITA STATE UNIVERSITY (US) | 2000-06-28 | — | — | EP | claimed |
| WO-1999009977-A9 | 1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE DERIVATIVES | UNIV WICHITA STATE (US) | 1999-06-24 | — | — | WO | claimed |
| WO-1999025728-A1 | NOVEL EXENDIN AGONIST COMPOUNDS | AMYLIN PHARMACEUTICALS, INC. (US) | 1999-05-27 | — | — | WO | claimed |
| US-5880095-A | Cholesteryl ester transfer protein inhibitor peptides and prophylactic and therapeutic anti-arteriosclerosis agents | LG CHEMICAL LTD. (KR) | 1999-03-09 | — | — | US | claimed |
| WO-1999009977-A1 | 1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE DERIVATIVES | WICHITA STATE UNIVERSITY (US) | 1999-03-04 | — | — | WO | claimed |
| WO-1996016980-A1 | MORPHOLINOETHYLAMIDE DERIVATIVES | NOVARTIS AG (CH) | 1996-06-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265563-A1 | METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM | GLP1R, IAPP, BDNF | DRD3 1253/4885HTR2A 124/4885DRD2 1324/4885 |
| US-20200046645-A1 | METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM | GLP1R, IAPP, BDNF | DRD3 1253/4885HTR2A 124/4885DRD2 1324/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | DRD3 1193/4885HTR2A 207/4885DRD2 911/4885 |
| US-20200038420-A1 | AMINOSTEROL COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING DEPRESSION | HSD17B7, CYP17A1, HSD17B2 | DRD3 798/4885HTR2A 199/4885DRD2 1735/4885 |
| US-11771657-B2 | Methods of delivering a neuroprotective polypeptide to the central nervous system | GLP1R, IAPP, BDNF | DRD3 1253/4885HTR2A 124/4885DRD2 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.